IL15 and prostate neoplasm: Cyto-IL-15 alone or in combination with cyto-abs, administered intratumorally in subcutaneous prostate tumors in mice, delayed tumor growth and increased survival by expanding the infiltration of NK and CD8+ T cells in the tumors leading to tumor necrosis (12).